MedTrace Logo

Irinotecan, Gemcitabine, Chemotherapy for Biliary Tract Cancer

NCT00832689 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2011-03-28

No results posted yet for this study

Summary

The study hypothesis is that chemotherapy of irinotecan and gemcitabine will improve local control of cancer and prolong survival in patients with inoperable biliary tract cancer.

Conditions

  • Biliary Tract Cancer

Interventions

DRUG

Irinotecan and Gemcitabine

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Jeong Youp Park, MD · Assistant professor of division of Gastroenterology

Study Design

Purpose
TREATMENT

Eligibility

Min Age
17 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-02-28
Completion
2010-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00832689 on ClinicalTrials.gov